Sone-214 ((exclusive)) -

Early preclinical studies have demonstrated the efficacy of Sone-214 in inhibiting tumor growth and reducing metastasis in a range of orthotopic and xenograft cancer models. For example, in NSCLC (non-small cell lung cancer) models, Sone-214 has been shown to reduce tumor burden by >50% compared to control animals, while also demonstrating potent anti-metastatic activity. Similarly, studies in breast cancer models have demonstrated that Sone-214 suppresses the growth of tumors and reduces the number of lung metastases by >70% compared to control animals.

The official listing is on the FANZA (formerly DMM) website, which is the primary distributor for JAV in Japan. sone-214

| Application | Rationale | Development status | |-------------|-----------|--------------------| | | STING activation amplifies antigen presentation and germinal‑center formation. SONE‑214’s oral route could allow “self‑adjuvanting” oral boosters. | Pre‑clinical proof‑of‑concept in mouse influenza vaccine (single oral dose → 2‑log reduction in viral load). | | Chronic viral infections (HBV, HCV, HIV latency reversal) | IFN‑β up‑regulation can suppress viral replication; STING activation may “shock” latent reservoirs. | In‑vitro latency reversal in HIV‑infected Jurkat cells; IND‑enabling toxicology for HBV underway. | | Auto‑immune modulation (e.g., SLE) | Low‑dose, biased STING agonism can re‑balance type I IFN pathways. | Early academic collaborations; no commercial program yet. | | Neurodegenerative disease (ALS, AD) | Emerging data suggest STING‑mediated clearance of cytosolic DNA from damaged mitochondria reduces neuroinflammation. | Proof‑of‑concept in SOD1‑G93A ALS mouse model (oral 10 mg/kg QD → delayed motor decline). | Early preclinical studies have demonstrated the efficacy of